首页> 外文OA文献 >A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

【2h】

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

机译：一项评估HER2阳性实体瘤患者的变构AKT抑制剂（MK-2206）与曲妥珠单抗联合使用的1期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Clifford Hudis; Charles Swanton; Yelena Y Janjigian; Ray Lee; Stephanie Sutherland; Robert Lehman; Sarat Chandarlapaty; Nicola Hamilton; Devika Gajria; James Knowles; Jigna Shah; Keith Shannon; Ernestina Tetteh; Daniel M Sullivan; Carolina Moreno; Li Yan; Hyo Sook Han;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors [J] . Clifford Hudis, Charles Swanton, Yelena Y Janjigian, Breast Cancer Research . 2013,第6期

机译：一项评估HER2阳性实体瘤患者的变构AKT抑制剂（MK-2206）和曲妥珠单抗联合使用的1期研究
2. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies [J] . Chien Amy Jo, Cockerill Alyson, Fancourt Craig, Breast cancer research and treatment. . 2016,第3期

机译：Akt抑制剂MK-2206与每周紫杉醇和曲妥珠单抗联合治疗晚期HER2扩增的实体瘤恶性肿瘤的1b期研究
3. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study [J] . Xu Na, Redfern Charles H., Gordon Michael, Cancer chemotherapy and pharmacology. . 2014,第6期

机译：曲妥珠单抗联合卡铂和多西他赛不能延长HER2阳性转移性或局部晚期不能手术的实体瘤患者的QT间隔：Ib期研究的结果
4. An Electrochemical Engineering Perspective of Nitric Oxide in Tumors: Why the Combination of an Allosteric Effector of Hemoglobin with Dietary Sodium Nitrite Should Be Effective in Treating Vascularized Tumors? [C] . Adam Heller Electrochemistry in medicine and biomedical applications . 2010

机译：肿瘤中一氧化氮的电化学工程观点：为什么将血红蛋白的变构效应物与饮食亚硝酸钠联合使用可有效治疗血管化肿瘤？
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors [O] . Clifford Hudis, Charles Swanton, Yelena Y Janjigian, 2013

机译：一项评估HER2阳性实体瘤患者的变构AKT抑制剂（MK-2206）与曲妥珠单抗联合使用的1期研究
7. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study [O] . 2014

机译：曲妥珠单抗联合卡铂和多西他赛不能延长HER2阳性转移性或局部晚期不能手术的实体瘤患者的QT间隔：Ib期研究的结果

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅